» Articles » PMID: 20042731

Acetylsalicylic Acid Enhances Purinergic Receptor-mediated Outward Currents in Rat Megakaryocytes

Overview
Specialties Cell Biology
Physiology
Date 2010 Jan 1
PMID 20042731
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purinergic receptor activation increases cytosolic Ca(2+) concentration in a fluctuating fashion, triggering oscillatory outward Ca(2+)-activated K(+) currents in rat megakaryocytes (MKs). Whole cell and nystatin-perforated patch-clamp techniques were used to analyze changes in ionic conductance in MK with acetylsalicylic acid (ASA), a cyclooxygenase-1 inhibitor and antithrombotic agent. MKs are a model for platelet reactivity, particularly in ASA treatment failure (ASA resistance). Freshly isolated MKs were incubated 30 min in the absence or presence of 1 mM ASA. Using a K(+)-rich internal solution, we recorded outward currents in response to 10 microM ATP, 10 microM ADP, and 5 microM 2-methyl-thio-ADP (2MeSADP) in the voltage-clamp mode. Agonist-induced currents decreased in amplitude over time, but this decline was attenuated by ASA in both continuous and repeated agonist challenge, indicating increased MK reactivity with ASA treatment. In separate experiments, heterologous desensitization was observed when MKs were stimulated with ADP after exposure to a thromboxane receptor agonist (U46619), indicating cross talk between thromboxane and purinergic pathways. Different cells, treated with ASA or MRS2179 (P2Y1 receptor antagonist), were stimulated with 2MeSADP. The dose-response curve was shifted to the left in both cases, suggesting increased MK reactivity. ASA also caused an increased interval between currents (delay). ASA attenuated desensitization of purinergic receptors and increased delay, again suggesting cross talk between purinergic and thromboxane pathways. These findings may be relevant to ASA resistance, because individual variations in sensitivity to the multiple effects of ASA on signaling pathways could result in insensitivity to its antiplatelet effects in some patients.

Citing Articles

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.

Sriram K, Insel P Physiol Rev. 2020; 101(2):545-567.

PMID: 33124941 PMC: 8238137. DOI: 10.1152/physrev.00035.2020.


Blood cells: an historical account of the roles of purinergic signalling.

Burnstock G Purinergic Signal. 2015; 11(4):411-34.

PMID: 26260710 PMC: 4648797. DOI: 10.1007/s11302-015-9462-7.

References
1.
Macintyre D, Rink T . The role of platelet membrane potential in the initiation of platelet aggregation. Thromb Haemost. 1982; 47(1):22-6. View

2.
Thomas D, Mason M, Mahaut-Smith M . Depolarisation-evoked Ca2+ waves in the non-excitable rat megakaryocyte. J Physiol. 2001; 537(Pt 2):371-8. PMC: 2278975. DOI: 10.1111/j.1469-7793.2001.00371.x. View

3.
Hardy A, Conley P, Luo J, Benovic J, Poole A, Mundell S . P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood. 2005; 105(9):3552-60. DOI: 10.1182/blood-2004-07-2893. View

4.
Mundell S, Jones M, Hardy A, Barton J, Beaucourt S, Conley P . Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol. 2006; 70(3):1132-42. DOI: 10.1124/mol.106.023549. View

5.
Kawa K . Discrete but simultaneous release of adenine nucleotides and serotonin from mouse megakaryocytes as detected with patch- and carbon-fiber electrodes. Am J Physiol Cell Physiol. 2003; 286(1):C119-28. DOI: 10.1152/ajpcell.00014.2003. View